Michael Pellini

Michael J.
Pellini currently works at American Cancer Society, Inc., as Director-at-Large from 2023, Mission Hospital Foundation, as Director, Personalized Medicine Coalition, as Director, Octave Bioscience, Inc., as Director from 2018, Vineti, Inc., as Director, Twinstrand Biosciences, Inc., as Director, Cradle Genomics, Inc., as Director, Octave Health Group, Inc., as Director, Nusano, Inc., as Director, Go2 Foundation For Lung Cancer, as Director, Exai Bio, Inc., as Director, Thomas Jefferson University, as Member-President Leadership Council, Boston College, as Member-Technology Council, Coriell Institute for Medical Research, as Trustee, and Section 32 LLC, as Managing Partner from 2017.
Dr. Pellini also formerly worked at Genomics Collaborative, Inc., as President & Chief Executive Officer from 1999 to 2004, Foundation Medicine, Inc., as Chairman from 2017 to 2018, Adaptive Biotechnologies Corp., as Independent Director from 2018 to 2025, Acelerate, Inc., as Director, Cira Discovery Sciences, Inc., as Director, Tango Therapeutics Sub, Inc., as Director from 2018 to 2021, Sema4 OpCo, Inc., as Director from 2019 to 2021, Thrive Earlier Detection Corp., as Director, GeneDx Holdings Corp., as Independent Director from 2021 to 2023, Singular Genomics Systems, Inc., as Lead Independent Director from 2017 to 2025, Safeguard Scientifics, Inc., as Vice President-Life Sciences Group from 2007 to 2008, Clarient, Inc., as President & Chief Operating Officer from 2009 to 2011, Ben Franklin Technology Partners, as Investment Committee Member, and PLUS Diagnostics, Inc., as Chief Operating Officer & Executive Vice President from 2005 to 2006.
Dr. Pellini received his Masters Business Admin degree in 1992 from Drexel University, undergraduate degree in 1987 from Boston College, and doctorate degree from Sidney Kimmel Medical College.